The GV-backed genomic editing technology developer has filed to raise up to $100m, adding to some $225m of venture funding in under three years.
US-based genetic therapy developer Beam Therapeutics has filed for a $100m initial public offering that would enable internet and technology group Alphabet and gene editing technology producer Editas to exit.
Beam is working on genetic medicines for serious diseases, using its genomic base editing platform to target point mutations, which it claims are responsible for nearly 60% of the human genetic errors associated with disease.
The technology was developed in the laboratories of co-founders David Liu, a professor of…
